The Ins and Outs of Cerebral Malaria Pathogenesis: Immunopathology, Extracellular Vesicles, Immunometabolism, and Trained Immunity
Conclusion and Future Directions The ECM model has produced a wealth of information on CM pathogenesis in mice with the aim to find an adjunctive therapy for HCM but its validity has been questioned. However, several investigators have provided a critical and evidence-based defense of this model (17, 128–131) and from knowledge gained from it, numerous laboratories have tested preclinical therapeutic interventions. Many have demonstrated efficacy at blocking the development of ECM but disappointingly, in a majority of cases, this was only found when administered before or early post infection and prior to the onset of clinical neurological signs. Therefore, only a few can justify, as therapies, a large-scale evaluation in HCM. A rare case of efficacy of treatment even when administered after the onset of clinical signs in the ECM model is the injection of IMP (52). The only other studies to date having demonstrated treatment efficacy after the onset of ECM have targeted CD8+ T cell binding to endothelial cells, and finally, immunometabolism. These successes have renewed hopes that the mouse model of ECM will continue to bring novel ideas/concepts which then will need to be confirmed or infirmed in HCM. For example, the characterization of retinal pathology in ECM (132) and (133), which was followed by the demonstration of its usefulness in HCM (134–137) (and many others) or MRI findings of brain alterations, originally described in 2005 for ECM (97), and followed...
Publication date: Available online 19 September 2020Source: European Journal of Surgical OncologyAuthor(s): Robert A. Nagourney, Steven Evans, Peter H. Tran, Adam J. Nagourney, Paul H. Sugarbaker
Conclusion: In conclusion, AVMD is a genotypic and phenotypic heterogeneous disease. The genetic aetiology could not be explained by sequencing BEST1 and PRPH2 genes in the AVMD patients; however, the variant of PRPH2 could be a cause of predisposition relevant to the phenotype. PMID: 32942919 [PubMed - as supplied by publisher]
CONCLUSION: Splenic fibrosis progresses along with advancement of PH. Cygb-expressing cells in the splenic cord possibly participate in this process through mechanisms including oxidative stress. PMID: 32945524 [PubMed - as supplied by publisher]
Authors: Teng M, Zhou S, Cai C, Lupien M, He HH Abstract Prostate cancer is the most commonly diagnosed non-cutaneous cancers in North American men. While androgen deprivation has remained as the cornerstone of prostate cancer treatment, resistance ensues leading to lethal disease. Forkhead box A1 (FOXA1) encodes a pioneer factor that induces open chromatin conformation to allow the binding of other transcription factors. Through direct interactions with the Androgen Receptor (AR), FOXA1 helps to shape AR signaling that drives the growth and survival of normal prostate and prostate cancer cells. FOXA1 also possesse...
Publication date: Available online 11 August 2020Source: Journal of Sport and Health ScienceAuthor(s): Edoardo Franceschetti, Edoardo Giovannetti de Sanctis, Alessio Palumbo, Michele Paciotti, Luca La Verde, Nicola Maffulli, Francesco Franceschi
Publication date: Available online 19 September 2020Source: The Journal of Molecular DiagnosticsAuthor(s): Iris van ’t Erve, Marjolein J.E. Greuter, Karen Bolhuis, Daan C.L. Vessies, Alessandro Leal, Geraldine R. Vink, Daan van den Broek, Victor E. Velculescu, Cornelis J.A. Punt, Gerrit A. Meijer, Veerle M.H. Coupé, Remond J.A. Fijneman
Publication date: Available online 19 September 2020Source: Pathology - Research and PracticeAuthor(s): Nazila Fathi Maroufi, Nima Ashouri, Zohreh Mortezania, Zahra Ashoori, Vahid Vahedian, Mohammad Taher Amirzadeh-Iranaq, Amir Fattahi, Hamid Kazemzadeh, Mariano Bizzarri, Maryam Akbarzadeh, Hamid Reza Nejabati, Yousef Faridvand, Mohammad-Reza Rashidi, Mohammad Nouri
Publication date: September 2020Source: Human Pathology: Case Reports, Volume 21Author(s): Yuri Noda, Yuko Nakanishi, Ayaka Izui, Hiroyo Takahashi, Chiya Oshiro, Hideo Inaji, Masaru Yamasaki
Conclusion: A nisin-producing probiotic, can be used to treat 'disease-altered' biofilms and promote healthier oral biofilms, which may be useful for improving patient oral health. PMID: 32944159 [PubMed]
Conclusions: Although morphological and biochemical tests are still used, they are associated with high-throughput sequencing techniques, due to their accuracy and time saving for profiling the predominant species in oral mycobiome. PMID: 32944157 [PubMed]
More News: African Health | Allergy & Immunology | Anemia | Ataxia | Australia Health | Brain | Brain Cancers | Cancer | Cancer & Oncology | Cancer in Adolescents | Cancer in Young Adults | Cancer Vaccines | Candida | Child Development | Children | Diets | Disability | Endemics | Environmental Health | Epidemiology | Epilepsy | Gastroschisis Repair | Genetics | Grants | High Fat | Infectious Diseases | International Medicine & Public Health | Jaundice | Kenya Health | Liver | Lupus | Malaria | Malaria Vaccine | Malawi Health | Medical Ethics | Men | Molecular Biology | Neurology | Neuroscience | Nutrition | Parasitic Diseases | Parasitology | Pathology | Pediatrics | PET Scan | Research | Respiratory Medicine | Science | Sports Medicine | Study | Thrombocytopenia | Training | Tuberculosis | Universities & Medical Training | Urology & Nephrology | Vaccines | Veterinary Vaccinations | Vitamin A | von Willebrand Disease | WHO